---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-014743"
form_type: "8-K"
ticker: null
cik: "0000764195"
company_name: "VBI Vaccines Inc/BC"
filed_at: "2024-04-16T23:59:59+00:00"
generated_at: "2026-06-03T22:38:16.563444+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# VBI Vaccines FY 2023 revenue $8.7M, net loss $92.8M; PreHevbrio sales up 234%

## Summary
- PreHevbrio net revenue $3.1M in 2023, up 234% YoY; Q1 2024 US volume ~65% of FY2023.
- VBI-1901 Phase 2b in GBM: 40% disease control (2/5 stable) vs 0% control; more data mid/year-end 2024.
- Agreement to sell Rehovot manufacturing to Brii Bio for up to $33M, reducing K2HV debt from $50M to $17M.
- Cash $23.7M at Dec 31, 2023 (down from $62.6M); net loss $92.8M ($6.03/share) vs $113.3M in 2022.
- R&D expense $9.3M (down 40%), SG&A $42.1M (down 25%) after April 2023 workforce reduction.

## SEC filing metadata
- accession: 0001493152-24-014743
- form_type: 8-K
- cik: 0000764195
- company_name: VBI Vaccines Inc/BC
- filed_at: 2024-04-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/764195/000149315224014743/0001493152-24-014743-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/764195/000149315224014743/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-014743
- JSON: https://secwatch.observer/filing/0001493152-24-014743.json
- Plain text: https://secwatch.observer/filing/0001493152-24-014743.txt

## Key facts
- Earnings Releases
  VBI Vaccines Inc/BC reported the year ended December 31, 2023 results: revenue $3.1 million.
  - Period: the year ended December 31, 2023
  - Revenue: $3.1 million
  - Result: reported results
  source text: Product revenue, net of $3.1 million in 2023 compared to $0.9 million in 2022, a 234% year-over-year increase
  evidence_url: https://www.sec.gov/Archives/edgar/data/764195/000149315224014743/0001493152-24-014743-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.